

19105737D

## SENATE BILL NO. 1557

AMENDMENT IN THE NATURE OF A SUBSTITUTE  
(Proposed by the Senate Committee on Education and Health  
on January 24, 2019)

(Patron Prior to Substitute—Senator Dunnavant)

A BILL to amend and reenact §§ 54.1-3408.3 and 54.1-3442.6 of the Code of Virginia, relating to Board of Pharmacy; cannabidiol oil and THC-A oil; regulation of pharmaceutical processors.

Be it enacted by the General Assembly of Virginia:

1. That §§ 54.1-3408.3 and 54.1-3442.6 of the Code of Virginia are amended and reenacted as follows:

§ 54.1-3408.3. Certification for use of cannabidiol oil or THC-A oil for treatment.

A. As used in this section:

"Cannabidiol oil" means a *any formulation of* processed Cannabis plant extract that contains at least 15 percent cannabidiol but no more than five percent tetrahydrocannabinol, or a dilution of the resin of the Cannabis plant that contains at least five milligrams of cannabidiol per ~~milliliter~~ dose but not more than five percent tetrahydrocannabinol.

"Practitioner" means a practitioner of medicine or osteopathy licensed by the Board of Medicine, a physician assistant licensed by the Board of Medicine, or a nurse practitioner jointly licensed by the Board of Medicine and the Board of Nursing.

"THC-A oil" means a *any formulation of* processed Cannabis plant extract that contains at least 15 percent tetrahydrocannabinol acid but not more than five percent tetrahydrocannabinol, or a dilution of the resin of the Cannabis plant that contains at least five milligrams of tetrahydrocannabinol acid per ~~milliliter~~ dose but not more than five percent tetrahydrocannabinol.

B. A practitioner in the course of his professional practice may issue a written certification for the use of cannabidiol oil or THC-A oil for treatment or to alleviate the symptoms of any diagnosed condition or disease determined by the practitioner to benefit from such use.

C. The written certification shall be on a form provided by the Office of the Executive Secretary of the Supreme Court developed in consultation with the Board of Medicine. Such written certification shall contain the name, address, and telephone number of the practitioner, the name and address of the patient issued the written certification, the date on which the written certification was made, and the signature of the practitioner. Such written certification issued pursuant to subsection B shall expire no later than one year after its issuance unless the practitioner provides in such written certification an earlier expiration.

D. No practitioner shall be prosecuted under § 18.2-248 or 18.2-248.1 for dispensing or distributing cannabidiol oil or THC-A oil for the treatment or to alleviate the symptoms of a patient's diagnosed condition or disease pursuant to a written certification issued pursuant to subsection B. Nothing in this section shall preclude the Board of Medicine from sanctioning a practitioner for failing to properly evaluate or treat a patient's medical condition or otherwise violating the applicable standard of care for evaluating or treating medical conditions.

E. A practitioner who issues a written certification to a patient pursuant to this section shall register with the Board. The Board shall, in consultation with the Board of Medicine, set a limit on the number of patients to whom a practitioner may issue a written certification.

F. A patient who has been issued a written certification shall register with the Board or, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, a patient's parent or legal guardian shall register and shall register such patient with the Board.

G. The Board shall promulgate regulations to implement the registration process. Such regulations shall include (i) a mechanism for sufficiently identifying the practitioner issuing the written certification, the patient being treated by the practitioner, and, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, the patient's parent or legal guardian; (ii) a process for ensuring that any changes in the information are reported in an appropriate timeframe; and (iii) a prohibition for the patient to be issued a written certification by more than one practitioner during any given time period.

H. Information obtained under the registration process shall be confidential and shall not be subject to the disclosure provisions of the Virginia Freedom of Information Act (§ 2.2-3700 et seq.). However, reasonable access to registry information shall be provided to (i) the Chairmen of the House and Senate Committees for Courts of Justice, (ii) state and federal agencies or local law enforcement for the purpose of investigating or prosecuting a specific individual for a specific violation of law, (iii) licensed physicians or pharmacists for the purpose of providing patient care and drug therapy management and monitoring of drugs obtained by a registered patient, (iv) a pharmaceutical processor involved in the treatment of a registered patient, or (v) a registered patient or, if such patient is a minor or an

60 incapacitated adult as defined in § 18.2-369, the patient's parent or legal guardian, but only with respect  
61 to information related to such registered patient.

62 **§ 54.1-3442.6. Permit to operate pharmaceutical processor.**

63 A. No person shall operate a pharmaceutical processor without first obtaining a permit from the  
64 Board. The application for such permit shall be made on a form provided by the Board and signed by a  
65 pharmacist who will be in full and actual charge of the pharmaceutical processor. The Board shall  
66 establish an application fee and other general requirements for such application.

67 B. Each permit shall expire annually on a date determined by the Board in regulation. The number of  
68 permits that the Board may issue or renew in any year is limited to one for each health service area  
69 established by the Board of Health. Permits shall be displayed in a conspicuous place on the premises of  
70 the pharmaceutical processor.

71 C. The Board shall adopt regulations establishing health, safety, and security requirements for  
72 pharmaceutical processors. Such regulations shall include requirements for (i) physical standards; (ii)  
73 location restrictions; (iii) security systems and controls; (iv) minimum equipment and resources; (v)  
74 recordkeeping; (vi) labeling and packaging; (vii) quarterly inspections; (viii) processes for safely and  
75 securely cultivating Cannabis plants intended for producing cannabidiol oil and THC-A oil, producing  
76 cannabidiol oil and THC-A oil, and dispensing and delivering in person cannabidiol oil and THC-A oil  
77 to a registered patient or, if such patient is a minor or an incapacitated adult as defined in § 18.2-369,  
78 such patient's parent or legal guardian; (ix) a maximum number of marijuana plants a pharmaceutical  
79 processor may possess at any one time; (x) the secure disposal of plant remains; ~~and~~ (xi) a process for  
80 registering a cannabidiol oil and THC-A oil product; *and (xii) dosage limitations, which shall provide*  
81 *that each dispensed dose of cannabidiol oil or THC-A not exceed 10 milligrams of*  
82 *tetrahydrocannabinol.*

83 D. Every pharmaceutical processor shall be under the personal supervision of a licensed pharmacist  
84 on the premises of the pharmaceutical processor.

85 E. The Board shall require an applicant for a pharmaceutical processor permit to submit to  
86 fingerprinting and provide personal descriptive information to be forwarded along with his fingerprints  
87 through the Central Criminal Records Exchange to the Federal Bureau of Investigation for the purpose  
88 of obtaining criminal history record information regarding the applicant. The cost of fingerprinting and  
89 the criminal history record search shall be paid by the applicant. The Central Criminal Records  
90 Exchange shall forward the results of the criminal history background check to the Board or its  
91 designee, which shall be a governmental entity.

92 F. No person who has been convicted of a felony or of any offense in violation of Article 1  
93 (§ 18.2-247 et seq.) or Article 1.1 (§ 18.2-265.1 et seq.) of Chapter 7 of Title 18.2 shall be employed by  
94 or act as an agent of a pharmaceutical processor.

95 **2. That the Secretary of Health and Human Resources and the Secretary of Agriculture and**  
96 **Forestry shall convene a work group to review and recommend an appropriate structure for an**  
97 **oversight organization for the medical marijuana program in Virginia. The work group shall**  
98 **report, by November 1, 2019, its findings and recommendations to the Chairmen of the Senate**  
99 **Committees on Agriculture, Conservation and Natural Resources and Education and Health and**  
100 **the House Committees on Agriculture, Chesapeake and Natural Resources and Health, Welfare**  
101 **and Institutions.**